Phase 2 Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
This clinical trial is testing a targeted medication called cabozantinib as a maintenance treatment for children and young adults with high-risk solid tumors. The goal is to see if this medicine can help prevent cancer from coming back after previous treatments.
This study is open to patients between 18 months and 40 years old who have specific high-risk solid tumors, such as neuroblastoma or soft tissue cancers. Participants also need to meet certain physical strength requirements and have fully recovered from past treatments.
Participants will take cabozantinib, which is a special type of medicine designed to block the signals that cancer cells need to grow and spread. Your doctors will closely monitor your health and recovery throughout the process.
The study is currently recruiting patients at locations in Birmingham, Alabama; Aurora, Colorado; and Washington, D.C. More locations may be available.
- 1Testing cabozantinib to prevent cancer recurrence
- 2For patients ages 18 months to 40 years with specific solid tumors
- 3Currently recruiting at select medical centers
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.